Taiho Oncology
Taiho Oncology, Inc.
202 Carnegie Center, Suite 100
Princeton, New Jersey 08540
Phone: (609) 750-5300Website: https://www.taihooncology.com/us/Careers: www.taihooncology.com/us/careers
Latest news
- FDA Approves Lonsurf (trifluridine/tipiracil) in Combination With Bevacizumab for Adult Patients With Metastatic Colorectal Cancer (mCRC)
2 August 2023 - FDA Approves Lonsurf (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
25 February 2019 - FDA Approves Lonsurf (tipiracil and trifluridine) for Advanced Colorectal Cancer
22 September 2015 - Taiho Oncology, Inc. Announces TAS-102 NDA for Refractory Metastatic Colorectal Cancer Accepted for Review by FDA
23 February 2015
Drugs Associated with Taiho Oncology, Inc.
Taiho Oncology, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
| Brand/Generic Name | Reviews | Rating |
|---|---|---|
|
Lonsurf
Generic name: tipiracil/trifluridine Drug class: antineoplastic combinations |
||
|
Lytgobi
Generic name: futibatinib Drug class: multikinase inhibitors |
||
| For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). | ||
